USADA announced today that Michael Kapes of Northport, FL, a U.S. athlete in the sport of BMX, has accepted a two-year period of ineligibility after testing positive for anabolic steroids during the Gator Nationals competition.
Kapes, 20, tested positive for Boldenone, and 19-norandrosterone, as the result of a urine sample collected at the National Bicycle League’s Gator Nationals on March 15, 2008 in West Palm Beach, FL. These are prohibited as anabolic steroids under the USADA Protocol and the Union Cycliste Internationale (UCI) Anti-Doping Rules, both of which have adopted the World Anti-Doping Code, and the WADA Prohibited List.
Kapes accepted the sanction which began on July 7, 2008, the day his provisional suspension was accepted, in accordance with the UCI (the sport’s international federation) rules for a first offense. He is also disqualified from all competitive results obtained on and subsequent to March 15, 2008, the day the sample was collected, including forfeiture of any medals, points and prizes.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website at usada.org on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance- enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited Substance Guide, easy-reference wallet cards, periodic newsletters, and complete athlete toolkits.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement. USADA is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
For more information or media inquiries, click here.